Iridian Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-247,086
| Closed | -$5.32M | – | 44 |
|
|
2025
Q4 | $5.32M | Sell |
247,086
-2,500
| -1% | -$48.5K | 1.96% | 17 |
|
|
2025
Q3 | $3.81M | Hold |
249,586
| – | – | 1.5% | 22 |
|
|
2025
Q2 | $2.21M | Hold |
249,586
| – | – | 0.77% | 32 |
|
|
2025
Q1 | $1.95M | Buy |
249,586
+80,000
| +47% | +$670K | 0.61% | 34 |
|
|
2024
Q4 | $1.78M | Buy |
169,586
+1,886
| +1% | +$22.9K | 0.47% | 36 |
|
|
2024
Q3 | $2.2M | Buy |
167,700
+50,000
| +42% | +$762K | 0.47% | 37 |
|
|
2024
Q2 | $1.65M | Buy |
117,700
+45,675
| +63% | +$745K | 0.37% | 38 |
|
|
2024
Q1 | $1.22M | Buy |
72,025
+18,574
| +35% | +$277K | 0.24% | 46 |
|
|
2023
Q4 | $755K | Buy |
53,451
+7,865
| +17% | +$92.4K | 0.14% | 45 |
|
|
2023
Q3 | $470K | Hold |
45,586
| – | – | 0.1% | 47 |
|
|
2023
Q2 | $751K | Buy |
+45,586
| New | +$593K | 0.07% | 43 |
|
|
2022
Q3 | – | Sell |
-30,000
| Closed | -$73K | – | 55 |
|
|
2022
Q2 | $73K | Buy |
+30,000
| New | +$123K | 0.01% | 51 |
|
|
2022
Q1 | – | Sell |
-22,279
| Closed | -$180K | – | 57 |
|
|
2021
Q4 | $180K | Sell |
22,279
-36,222
| -62% | -$331K | 0.01% | 74 |
|
|
2021
Q3 | $573K | Sell |
58,501
-172,572
| -75% | -$1.36M | 0.02% | 74 |
|
|
2021
Q2 | $1.55M | Sell |
231,073
-12,995
| -5% | -$103K | 0.03% | 65 |
|
|
2021
Q1 | $2.21M | Sell |
244,068
-101,699
| -29% | -$822K | 0.04% | 69 |
|
|
2020
Q4 | $2.31M | Buy |
345,767
+186,567
| +117% | +$1.17M | 0.04% | 63 |
|
|
2020
Q3 | $802K | Hold |
159,200
| – | – | 0.02% | 65 |
|
|
2020
Q2 | $1.29M | Buy |
159,200
+98,600
| +163% | +$869K | 0.03% | 58 |
|
|
2020
Q1 | $481K | Sell |
60,600
-249,869
| -80% | -$1.92M | 0.01% | 67 |
|
|
2019
Q4 | $2.34M | Buy |
+310,469
| New | +$1.64M | 0.04% | 54 |
|
|
2015
Q4 | – | Sell |
-26,480
| Closed | -$432K | – | 69 |
|
|
2015
Q3 | $432K | Hold |
26,480
| – | – | ﹤0.01% | 65 |
|
|
2015
Q2 | $561K | Sell |
26,480
-3,580
| -12% | -$64.2K | ﹤0.01% | 71 |
|
|
2015
Q1 | $540K | Sell |
30,060
-1,470
| -5% | -$23K | ﹤0.01% | 46 |
|
|
2014
Q4 | $540K | Sell |
31,530
-26,740
| -46% | -$382K | 0.01% | 48 |
|
|
2014
Q3 | $834K | Sell |
58,270
-1,550
| -3% | -$22.3K | 0.01% | 49 |
|
|
2014
Q2 | $897K | Sell |
59,820
-43,200
| -42% | -$521K | 0.01% | 47 |
|
|
2014
Q1 | $1.38M | Sell |
103,020
-54,310
| -35% | -$582K | 0.02% | 44 |
|
|
2013
Q4 | $1.27M | Buy |
157,330
+20,050
| +15% | +$142K | 0.02% | 44 |
|
|
2013
Q3 | $901K | Buy |
137,280
+14,110
| +11% | +$86.8K | 0.01% | 46 |
|
|
2013
Q2 | $756K | Buy |
+123,170
| New | +$636K | 0.01% | 48 |
|
Other funds holding AVDL
Iridian Asset Management's AVDL Position: Q1 2026 in Review
Iridian Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 247,086 shares — an estimated $5.32M sold.
Iridian Asset Management first reported a position in AVDL in Q2 2013 and held it in 31 quarters. The position peaked at $5.32M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Iridian Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Iridian Asset Management sold 247,086 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
- Iridian Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- Iridian Asset Management's Avadel Pharmaceuticals position peaked at $5.32M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.